Postsynaptic 5‐hydroxytryptamine1A receptor activation increases in vivo dopamine release in rat prefrontal cortex
- 1 March 2000
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 129 (5) , 1028-1034
- https://doi.org/10.1038/sj.bjp.0703139
Abstract
5‐Hydroxytryptamine (5‐HT) plays a role in the regulation of 3,4‐dihydroxyphenylethylamine (dopamine) neurons in the brain, but the precise mechanism of regulation by 5‐HT1A receptors of dopamine release has not been defined. The present study describes the effect of 5‐{3‐[[(2S)‐1,4‐benzodioxan‐2ylmethyl]amino]propoxy}‐1,3‐benzodioxole HCl (MKC‐242), a highly potent and selective 5‐HT1A receptor agonist, on dopamine release in the prefrontal cortex using microdialysis in the freely moving rat. Subcutaneous injection of MKC‐242 (0.3–1.0 mg kg−1) increased extracellular levels of dopamine in the prefrontal cortex. The effect of MKC‐242 in the prefrontal cortex was antagonized by pretreatment with the selective 5‐HT1A receptor antagonist, N‐[2‐[4‐(2‐methoxyphenyl)‐1‐piperazinyl]ethyl]‐N‐(2‐pyridinyl)cyclohexanecarboxamide (WAY100635; 1 mg kg−1, i.p.). Local application of WAY100635 (10 μM) via a microdialysis probe antagonized the effect of systemic MKC‐242 in an increasing dopamine release, and locally infused 8‐hydroxy‐2‐(di‐n‐propylamino)tetralin (10 μM) increased dopamine release in the prefrontal cortex. MKC‐242 increased cortical dopamine release in the rats pretreated with 5,7‐dihydroxytryptamine (150 μg, i.c.v.) that caused an almost complete reduction in cortical 5‐HT content. The effect of MKC‐242 to increase dopamine release was also observed in the hippocampus, but not in the striatum or nucleus accumbens. Fluoxetine, a selective serotonin reuptake inhibitor, increased dopamine release in the prefrontal cortex, but not in the nucleus accumbens, while buspirone, a 5‐HT1A receptor agonist, increased dopamine release in both brain regions. The present results indicate that activation of postsynaptic 5‐HT1A receptors increases dopamine release in a brain region‐specific manner. British Journal of Pharmacology (2000) 129, 1028–1034; doi:10.1038/sj.bjp.0703139Keywords
This publication has 46 references indexed in Scilit:
- Reduction of Wrap Restraint Stress-Induced Defecation by MKC-242, a Novel Benzodioxan Derivative, via 5-HT1A-Receptor Agonist Action in RatsThe Japanese Journal of Pharmacology, 1998
- Dopamine, the prefrontal cortex and schizophreniaJournal of Psychopharmacology, 1997
- Effect of conditioned fear stress on dopamine release in the rat prefrontal cortexNeuroscience Letters, 1996
- Monoamine Interactions Measured by Microdialysis in the Ventral Tegmental Area of Rats Treated Systemically with (±)‐8‐Hydroxy‐2‐(Di‐n‐Propylamino)tetralinJournal of Neurochemistry, 1995
- Novel Benzodioxan Derivative, 5-{3-[((2S)-1,4-Benzodioxan-2-ylmethyl)amino]propoxy}-l,3-benzodioxole HC1 (MKC-242), with a Highly Potent and Selective Agonist Activity at Rat Central Serotonin1A ReceptorsThe Japanese Journal of Pharmacology, 1995
- The Anxiogenic β‐Carboline FG 7142 Selectively Increases Dopamine Release in Rat Prefrontal Cortex as Measured by MicrodialysisJournal of Neurochemistry, 1991
- Serotonin Agents in AnxietyAnnals of the New York Academy of Sciences, 1990
- Multiple and complex effects of buspirone on central dopaminergic systemPharmacology Biochemistry and Behavior, 1988
- Dopamine and depression: A review of recent evidence. III. The effects of antidepressant treatmentsBrain Research Reviews, 1983
- Differential Effects of Classical and Atypical Antipsychotic Drugs on A9 and A10 Dopamine NeuronsScience, 1983